Kailera Therapeutics, Inc. (KLRA)
Price History
Apr 19, 2026 — Sep 1, 2026Investment Snapshot
- P/B of 2.25 — trading above book value
- Piotroski F-Score 0/9 — signs of financial weakness
- Loss-making — negative ROE of -21.2%
Kailera Therapeutics, Inc. (KLRA) is a publicly traded company, listed on the NASDAQ , with a market capitalisation of $2.5 billion . Key value metrics: P/B ratio 2.25, Piotroski F-Score 0 out of 9 .
Value Score
Key Metrics
Kailera Therapeutics, Inc. — Fundamental Analysis Summary
On financial health, KLRA shows a weak Piotroski F-Score of 0/9, a signal of deteriorating financial health, and negative return on equity of -21.2%.
StockPik's composite Value Score for KLRA is 40/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.